Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Phase 4 Unknown 61 enrolled CHA University Hanlim Pharm. Co., Ltd. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-T Eye drops 0.15% and ALPHAGAN-P Eye drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Timeline

Start: 2019-03-20
Primary completion: 2021-01-29
Completion: 2021-01-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Brimonidine	Small molecule	1.5 mg	Other

Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Summary

Timeline

Drugs

Indications